Print Page    E-mail Page    RSS    E-mail Alerts 


Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

Stock Quotemore >
 Stock is Down 0.06 (5.56%)
Bellerophon (Nasdaq: BLPH)
Data as of 10/17/18 1:15 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Enrollment of the Planned 40 Subjects Completed, with Top-line Data Expected in January 2019 WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH... 
Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference
WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel. Bellerophon Presentation Details Date:  Wednesday, September 5 Time:  9:10am Eastern Tim... 
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified interim analysis from the first 75 enrolled subjects completing 16-weeks of treatment in the Phase 3 INOvation-1 study evaluating INOpulse® for the treatment of pulmonary arterial hypertension (PAH). The DMC has recommended that the tria... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources